Xenon Pharmaceuticals (XENE) Short term Debt (2017 - 2020)

Xenon Pharmaceuticals' (XENE) quarterly Short term Debt came in at $15.7 million in Q1 2020, up 237.12% on a QoQ basis from $4.6 million in Q4 2019.

Xenon Pharmaceuticals (XENE) Short term Debt (2017 - 2020) Analysis & Trends

Xenon Pharmaceuticals (XENE) has 4 years of Short term Debt data on file, last reported at $15.7 million in Q1 2020.

On a quarterly basis, Short term Debt changed N/A year-over-year to $15.7 million in Q1 2020; TTM through Mar 2020 was $15.7 million, a N/A change from a year earlier, with the FY2019 full-year figure at $4.6 million, changed N/A from the prior year.
Short term Debt for Q1 2020 stood at $15.7 million, up from $4.6 million in the prior quarter.
Over the last five years, Short term Debt for XENE reached as high as $15.7 million in Q1 2020 and fell as low as $700000.0 in Q4 2017.
Historically, Short term Debt has averaged $4.7 million across 4 years, with a median of $2.8 million in 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Xenon Pharmaceuticals	5.71 Bn	5.71 Bn	-

Download Data